Thousand Oaks-based Amgen has entered into two new collaborations, one involving treatment for colon cancer and another regarding therapies for inflammatory bowel disease.
By Stephen Nellis / Friday, January 17th, 2014 / Technology, Top Stories / Comments Off on Round 2: Atara raises $13.5M as T.O. biotech boom takes hold
Thousand Oaks-based Atara Biotherapeutics has brought on more investors to its second financing round, bringing the total raised to $52 million.
Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
A device made by Santa Barbara-based Active Life Scientific played a critical role in a new study at the Mayo Clinic linking Type 2 diabetes to bone problems.
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
ImmunGene’s so-called antibody-cytokine fusion technology could help improve the cancer-cell targeting in therapies. President and CEO Sanjay D. Khare was formerly the scientific director at Amgen, the biotech giant. Prior to the funding, ImmunGene had received several hundred thousand dollars in federal research grants.
